BioMedNewsBreaks

TuesdaySep 08, 2026 9:20 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) was featured in BioMedWire editorial coverage highlighting FDA clearance of the company Investigational New Drug (“IND”) application to begin a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in people with multiple sclerosis (“MS”). Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (“PAD2”) and target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with the company reporting favorable…

Continue Reading

FridaySep 04, 2026 10:10 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Expands Nanox.ARC Distribution in New England

Nanox (NASDAQ: NNOX), through its U.S.-based subsidiary Nanox Impact Inc., entered into a distribution agreement with Associated X-Ray Imaging Corp. to support deployment of the Nanox.ARC across New England. Under the agreement, Associated X-Ray Imaging will market, distribute and support the FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its regional customer relationships and service infrastructure. The agreement expands Nanox’s U.S. channel partner network and is intended to increase access to the Nanox.ARC in outpatient and community-based clinical settings across targeted markets. To view the full press release, visit https://ibn.fm/ChGtd About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s…

Continue Reading

FridaySep 04, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in…

Continue Reading

WednesdaySep 02, 2026 3:44 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care

Regentis Biomaterials (NYSE American: RGNT) is advancing a regenerative approach to cartilage repair with GelrinC, a cell-free, off-the-shelf hydrogel implant designed to create a temporary environment that supports the body’s natural ability to regenerate damaged knee cartilage. Unlike conventional implants that primarily replace or reinforce damaged tissue, GelrinC is injected into a cartilage lesion and cured in place with ultraviolet light before gradually degrading as new tissue develops. The company reports encouraging clinical results, including greater pain improvement versus microfracture at two years and MRI evidence of cartilage regeneration. GelrinC already has CE Mark approval in Europe, where Regentis is preparing for…

Continue Reading

WednesdaySep 02, 2026 10:44 am

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Shareholders Approve Uplisting Strategy, Series B Preferred Stock Retirement

Earth Science Tech (OTC: ETST) announced voting results from its first Annual Meeting of Stockholders, held virtually Aug. 31, 2026. Shareholders approved the company pursuit of a reverse stock split, valid for 12 months and to be used only if the board determines it is necessary to meet minimum bid-price requirements for an uplisting to a national securities exchange. Shareholders also authorized the board independent Special Committee to negotiate the retirement of the Series B Preferred Stock, which the company said would eliminate its dual-class, super-voting control structure. Shareholders also approved the company cash-only “Say-on-Pay” executive compensation structure and elected a three-year review cycle, re-elected all seven director nominees and ratified Semple, Marchal…

Continue Reading

MondayAug 31, 2026 12:15 pm

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) received a ‘Buy’ rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis, an area where therapeutic options remain limited. The firm’s $8.00 price target reflects its valuation of Quantum BioPharma’s development pipeline. For more information on Lucid-MS, visit https://ibn.fm/8uqwL About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

Continue Reading

ThursdayAug 27, 2026 3:41 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S.…

Continue Reading

ThursdayAug 27, 2026 3:12 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40 enrolled patients closely match the historical control group in baseline characteristics. In Europe, where GelrinC already has CE Mark approval, Regentis is preparing for broader commercialization through surgeon training, an expanding network of Centers of Excellence…

Continue Reading

ThursdayAug 27, 2026 2:32 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position among OTC-listed companies through consistent financial growth, timely reporting, vertical integration, prudent capital allocation, and ownership of hard real estate assets. Revenue increased to $35.7 million in FY2026 from $33.1 million in FY2025 and $11.95 million in FY2024, while gross profit rose to $25.5 million from $24.3 million and $7.8 million. The company attributes this progress to strategic investments and acquisitions made without adding debt, particularly its purchase of Avenvi, a real estate company whose 13-property portfolio includes the Texas property housing ETST’s Mister Meds…

Continue Reading

ThursdayAug 27, 2026 12:00 pm

BioMedNewsBreaks – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Completes Three Large-Animal Procedures Using StereoCED(TM) Platform

NeuroOne (NASDAQ: NMTC) reported the successful completion of three large-animal procedures using its next-generation StereoCED(TM) platform as part of an ongoing preclinical epilepsy research program at the University of Minnesota. In two procedures, NeuroOne drug delivery electrodes delivered a study agent directly into targeted brain tissue while also recording intracranial electrophysiological activity from the same regions, a combination the company believes has not previously been demonstrated in convection-enhanced delivery. The procedures were designed to establish technical feasibility and validate the integrated surgical and drug delivery workflow. NeuroOne said the repeatability demonstrated across the three procedures provides additional confidence as it advances toward the planned launch of StereoCED(TM) for human investigational clinical studies later this quarter. Development…

Continue Reading